RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Astellas Pharma Stock

Astellas Pharma EBIT 2024

Astellas Pharma EBIT

124.61 B JPY

Ticker

4503.T

ISIN

JP3942400007

WKN

856273

In 2024, Astellas Pharma's EBIT was 124.61 B JPY, a -46.21% increase from the 231.65 B JPY EBIT recorded in the previous year.

The Astellas Pharma EBIT history

YEAREBIT (undefined JPY)
2027e477.92
2026e441.88
2025e328.76
2024124.61
2023231.65
2022218.15
2021250.93
2020267.48
2019288.23
2018277.69
2017273.81
2016267.18
2015210.64
2014187.83
2013153.87
2012131.52
2011119.18
2010186.41
2009250.4
2008275.91
2007189.39
2006190.4
200596.1

Astellas Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Astellas Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Astellas Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Astellas Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Astellas Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Astellas Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Astellas Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Astellas Pharma’s growth potential.

Astellas Pharma Revenue, EBIT and net profit per share

DateAstellas Pharma RevenueAstellas Pharma EBITAstellas Pharma Net Income
2027e1.97 T undefined477.92 B undefined210.55 B undefined
2026e1.84 T undefined441.88 B undefined146.71 B undefined
2025e1.78 T undefined328.76 B undefined66.29 B undefined
20241.6 T undefined124.61 B undefined17.05 B undefined
20231.52 T undefined231.65 B undefined98.71 B undefined
20221.3 T undefined218.15 B undefined124.09 B undefined
20211.25 T undefined250.93 B undefined120.59 B undefined
20201.3 T undefined267.48 B undefined195.41 B undefined
20191.31 T undefined288.23 B undefined222.27 B undefined
20181.3 T undefined277.69 B undefined164.68 B undefined
20171.31 T undefined273.81 B undefined218.7 B undefined
20161.37 T undefined267.18 B undefined193.69 B undefined
20151.25 T undefined210.64 B undefined135.86 B undefined
20141.14 T undefined187.83 B undefined90.87 B undefined
20131.01 T undefined153.87 B undefined82.85 B undefined
2012969.39 B undefined131.52 B undefined78.23 B undefined
2011953.95 B undefined119.18 B undefined67.65 B undefined
2010974.88 B undefined186.41 B undefined122.26 B undefined
2009965.7 B undefined250.4 B undefined170.99 B undefined
2008972.59 B undefined275.91 B undefined177.44 B undefined
2007920.62 B undefined189.39 B undefined131.29 B undefined
2006879.36 B undefined190.4 B undefined103.57 B undefined
2005447.05 B undefined96.1 B undefined33.67 B undefined

Astellas Pharma stock margins

The Astellas Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Astellas Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Astellas Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Astellas Pharma's sales revenue. A higher gross margin percentage indicates that the Astellas Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Astellas Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Astellas Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Astellas Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Astellas Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Astellas Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Astellas Pharma Margin History

Astellas Pharma Gross marginAstellas Pharma Profit marginAstellas Pharma EBIT marginAstellas Pharma Profit margin
2027e81.76 %24.26 %10.69 %
2026e81.76 %24.03 %7.98 %
2025e81.76 %18.51 %3.73 %
202481.76 %7.77 %1.06 %
202381.01 %15.25 %6.5 %
202280.48 %16.83 %9.57 %
202180.31 %20.08 %9.65 %
202078.73 %20.56 %15.02 %
201977.64 %22.06 %17.01 %
201877.37 %21.36 %12.66 %
201775.57 %20.88 %16.67 %
201675.55 %19.46 %14.11 %
201573.29 %16.89 %10.89 %
201471 %16.48 %7.97 %
201367.77 %15.3 %8.24 %
201267.13 %13.57 %8.07 %
201168.97 %12.49 %7.09 %
201070.33 %19.12 %12.54 %
200972.62 %25.93 %17.71 %
200871.28 %28.37 %18.24 %
200769.02 %20.57 %14.26 %
200668.66 %21.65 %11.78 %
200568.13 %21.5 %7.53 %

Astellas Pharma Aktienanalyse

What does Astellas Pharma do?

Astellas Pharma Inc. is a global pharmaceutical company based in Tokyo, Japan. The company manufactures and distributes medications worldwide. It was formed in April 2005 through the merger of two well-known Japanese pharmaceutical companies - Yamanouchi and Fujisawa. This merger created one of Japan's largest pharmaceutical companies and allowed for collaboration on the global market and the development of new innovations in medication research. Astellas' business model is focused on targeted research and development, comprehensive marketing and distribution networks, and collaboration with international partners. The company's main areas of focus are cancer, urology, transplantation, anti-infectives, and pneumology. Astellas has expanded its business through acquisitions and partnerships and currently operates in over 50 countries worldwide. In addition to pharmaceutical production, the company also provides services and consulting in the medical and health sectors. Astellas' business is divided into segments including pharmaceuticals, medical devices, and diagnostics. The pharmaceutical segment is the largest and offers a wide range of prescription medications for various medical areas. The medical devices segment specializes in the development and manufacturing of medical devices such as catheters, stents, and heart valves. The diagnostics segment focuses on developing and producing testing systems and instruments for diseases such as HIV and infectious diseases. Overall, Astellas is an important player in the global pharmaceutical and health industry, known for its innovative research, wide range of products, and collaboration with partners to develop campaigns against various diseases. Astellas Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Astellas Pharma's EBIT

Astellas Pharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Astellas Pharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Astellas Pharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Astellas Pharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Astellas Pharma stock

How much did Astellas Pharma achieve in EBIT for the current year?

In the current year, Astellas Pharma has achieved an EBIT of 124.61 B JPY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Astellas Pharma.

How has the EBIT of Astellas Pharma developed in recent years?

The EBIT of Astellas Pharma has increased by -46.209% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Astellas Pharma?

The EBIT of Astellas Pharma is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Astellas Pharma pay?

Over the past 12 months, Astellas Pharma paid a dividend of 72 JPY . This corresponds to a dividend yield of about 4.67 %. For the coming 12 months, Astellas Pharma is expected to pay a dividend of 73.66 JPY.

What is the dividend yield of Astellas Pharma?

The current dividend yield of Astellas Pharma is 4.67 %.

When does Astellas Pharma pay dividends?

Astellas Pharma pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Astellas Pharma?

Astellas Pharma paid dividends every year for the past 23 years.

What is the dividend of Astellas Pharma?

For the upcoming 12 months, dividends amounting to 73.66 JPY are expected. This corresponds to a dividend yield of 4.78 %.

In which sector is Astellas Pharma located?

Astellas Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Astellas Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Astellas Pharma from 12/1/2024 amounting to 37 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Astellas Pharma pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Astellas Pharma in the year 2023?

In the year 2023, Astellas Pharma distributed 65 JPY as dividends.

In which currency does Astellas Pharma pay out the dividend?

The dividends of Astellas Pharma are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Astellas Pharma stock can be added to a savings plan with the following providers: Consorsbank

Andere Kennzahlen von Astellas Pharma

Our stock analysis for Astellas Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Astellas Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.